Global Tumor Immunotherapy Drugs Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Tumor Immunotherapy Drugs market size was valued at USD 43830 million in 2022 and is forecast to a readjusted size of USD 77680 million by 2029 with a CAGR of 8.5% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Tumor immunotherapy refers to destroying cancer cells by stimulating and activating the patient's own immune system.
This report is a detailed and comprehensive analysis for global Tumor Immunotherapy Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Tumor Immunotherapy Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Tumor Immunotherapy Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Tumor Immunotherapy Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Tumor Immunotherapy Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023.
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Tumor Immunotherapy Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace.
This report profiles key players in the global Tumor Immunotherapy Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bristol Myer Squibb, AstraZeneca, Merck, Roche / Genentech and Ono Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Tumor Immunotherapy Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Tumor Immunotherapy Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Tumor Immunotherapy Drugs, with price, sales, revenue and global market share of Tumor Immunotherapy Drugs from 2018 to 2023.
Chapter 3, the Tumor Immunotherapy Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Tumor Immunotherapy Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Tumor Immunotherapy Drugs market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Tumor Immunotherapy Drugs.
Chapter 14 and 15, to describe Tumor Immunotherapy Drugs sales channel, distributors, customers, research findings and conclusion.
Tumor immunotherapy refers to destroying cancer cells by stimulating and activating the patient's own immune system.
This report is a detailed and comprehensive analysis for global Tumor Immunotherapy Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Tumor Immunotherapy Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Tumor Immunotherapy Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Tumor Immunotherapy Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Tumor Immunotherapy Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023.
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Tumor Immunotherapy Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace.
This report profiles key players in the global Tumor Immunotherapy Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bristol Myer Squibb, AstraZeneca, Merck, Roche / Genentech and Ono Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Tumor Immunotherapy Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Immune Checkpoint Inhibitors
- Tumor Vaccine
- Adoptive Immunotherapy
- Non-specific Immunomodulator
- Hospital
- Clinic
- Other
- Bristol Myer Squibb
- AstraZeneca
- Merck
- Roche / Genentech
- Ono Pharmaceutical
- Regeneron
- Innovent
- Hengrui Medicine
- Junshi Biosciences
- Pfizer, Inc
- F. Hoffmann-La Roche Ltd
- Incyte Corporation
- NewLink Genetics Corporation
- Celldex Therapeutics, Inc
- GlaxoSmithKline
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Tumor Immunotherapy Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Tumor Immunotherapy Drugs, with price, sales, revenue and global market share of Tumor Immunotherapy Drugs from 2018 to 2023.
Chapter 3, the Tumor Immunotherapy Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Tumor Immunotherapy Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Tumor Immunotherapy Drugs market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Tumor Immunotherapy Drugs.
Chapter 14 and 15, to describe Tumor Immunotherapy Drugs sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Tumor Immunotherapy Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Tumor Immunotherapy Drugs Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Immune Checkpoint Inhibitors
1.3.3 Tumor Vaccine
1.3.4 Adoptive Immunotherapy
1.3.5 Non-specific Immunomodulator
1.4 Market Analysis by Application
1.4.1 Overview: Global Tumor Immunotherapy Drugs Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Other
1.5 Global Tumor Immunotherapy Drugs Market Size & Forecast
1.5.1 Global Tumor Immunotherapy Drugs Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Tumor Immunotherapy Drugs Sales Quantity (2018-2029)
1.5.3 Global Tumor Immunotherapy Drugs Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 Bristol Myer Squibb
2.1.1 Bristol Myer Squibb Details
2.1.2 Bristol Myer Squibb Major Business
2.1.3 Bristol Myer Squibb Tumor Immunotherapy Drugs Product and Services
2.1.4 Bristol Myer Squibb Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Bristol Myer Squibb Recent Developments/Updates
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Tumor Immunotherapy Drugs Product and Services
2.2.4 AstraZeneca Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 AstraZeneca Recent Developments/Updates
2.3 Merck
2.3.1 Merck Details
2.3.2 Merck Major Business
2.3.3 Merck Tumor Immunotherapy Drugs Product and Services
2.3.4 Merck Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Merck Recent Developments/Updates
2.4 Roche / Genentech
2.4.1 Roche / Genentech Details
2.4.2 Roche / Genentech Major Business
2.4.3 Roche / Genentech Tumor Immunotherapy Drugs Product and Services
2.4.4 Roche / Genentech Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Roche / Genentech Recent Developments/Updates
2.5 Ono Pharmaceutical
2.5.1 Ono Pharmaceutical Details
2.5.2 Ono Pharmaceutical Major Business
2.5.3 Ono Pharmaceutical Tumor Immunotherapy Drugs Product and Services
2.5.4 Ono Pharmaceutical Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Ono Pharmaceutical Recent Developments/Updates
2.6 Regeneron
2.6.1 Regeneron Details
2.6.2 Regeneron Major Business
2.6.3 Regeneron Tumor Immunotherapy Drugs Product and Services
2.6.4 Regeneron Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Regeneron Recent Developments/Updates
2.7 Innovent
2.7.1 Innovent Details
2.7.2 Innovent Major Business
2.7.3 Innovent Tumor Immunotherapy Drugs Product and Services
2.7.4 Innovent Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Innovent Recent Developments/Updates
2.8 Hengrui Medicine
2.8.1 Hengrui Medicine Details
2.8.2 Hengrui Medicine Major Business
2.8.3 Hengrui Medicine Tumor Immunotherapy Drugs Product and Services
2.8.4 Hengrui Medicine Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Hengrui Medicine Recent Developments/Updates
2.9 Junshi Biosciences
2.9.1 Junshi Biosciences Details
2.9.2 Junshi Biosciences Major Business
2.9.3 Junshi Biosciences Tumor Immunotherapy Drugs Product and Services
2.9.4 Junshi Biosciences Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Junshi Biosciences Recent Developments/Updates
2.10 Pfizer, Inc
2.10.1 Pfizer, Inc Details
2.10.2 Pfizer, Inc Major Business
2.10.3 Pfizer, Inc Tumor Immunotherapy Drugs Product and Services
2.10.4 Pfizer, Inc Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Pfizer, Inc Recent Developments/Updates
2.11 F. Hoffmann-La Roche Ltd
2.11.1 F. Hoffmann-La Roche Ltd Details
2.11.2 F. Hoffmann-La Roche Ltd Major Business
2.11.3 F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Product and Services
2.11.4 F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
2.12 Incyte Corporation
2.12.1 Incyte Corporation Details
2.12.2 Incyte Corporation Major Business
2.12.3 Incyte Corporation Tumor Immunotherapy Drugs Product and Services
2.12.4 Incyte Corporation Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Incyte Corporation Recent Developments/Updates
2.13 NewLink Genetics Corporation
2.13.1 NewLink Genetics Corporation Details
2.13.2 NewLink Genetics Corporation Major Business
2.13.3 NewLink Genetics Corporation Tumor Immunotherapy Drugs Product and Services
2.13.4 NewLink Genetics Corporation Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 NewLink Genetics Corporation Recent Developments/Updates
2.14 Celldex Therapeutics, Inc
2.14.1 Celldex Therapeutics, Inc Details
2.14.2 Celldex Therapeutics, Inc Major Business
2.14.3 Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Product and Services
2.14.4 Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Celldex Therapeutics, Inc Recent Developments/Updates
2.15 GlaxoSmithKline
2.15.1 GlaxoSmithKline Details
2.15.2 GlaxoSmithKline Major Business
2.15.3 GlaxoSmithKline Tumor Immunotherapy Drugs Product and Services
2.15.4 GlaxoSmithKline Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 GlaxoSmithKline Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: TUMOR IMMUNOTHERAPY DRUGS BY MANUFACTURER
3.1 Global Tumor Immunotherapy Drugs Sales Quantity by Manufacturer (2018-2023)
3.2 Global Tumor Immunotherapy Drugs Revenue by Manufacturer (2018-2023)
3.3 Global Tumor Immunotherapy Drugs Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Tumor Immunotherapy Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Tumor Immunotherapy Drugs Manufacturer Market Share in 2022
3.4.2 Top 6 Tumor Immunotherapy Drugs Manufacturer Market Share in 2022
3.5 Tumor Immunotherapy Drugs Market: Overall Company Footprint Analysis
3.5.1 Tumor Immunotherapy Drugs Market: Region Footprint
3.5.2 Tumor Immunotherapy Drugs Market: Company Product Type Footprint
3.5.3 Tumor Immunotherapy Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Tumor Immunotherapy Drugs Market Size by Region
4.1.1 Global Tumor Immunotherapy Drugs Sales Quantity by Region (2018-2029)
4.1.2 Global Tumor Immunotherapy Drugs Consumption Value by Region (2018-2029)
4.1.3 Global Tumor Immunotherapy Drugs Average Price by Region (2018-2029)
4.2 North America Tumor Immunotherapy Drugs Consumption Value (2018-2029)
4.3 Europe Tumor Immunotherapy Drugs Consumption Value (2018-2029)
4.4 Asia-Pacific Tumor Immunotherapy Drugs Consumption Value (2018-2029)
4.5 South America Tumor Immunotherapy Drugs Consumption Value (2018-2029)
4.6 Middle East and Africa Tumor Immunotherapy Drugs Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2029)
5.2 Global Tumor Immunotherapy Drugs Consumption Value by Type (2018-2029)
5.3 Global Tumor Immunotherapy Drugs Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2029)
6.2 Global Tumor Immunotherapy Drugs Consumption Value by Application (2018-2029)
6.3 Global Tumor Immunotherapy Drugs Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2029)
7.2 North America Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2029)
7.3 North America Tumor Immunotherapy Drugs Market Size by Country
7.3.1 North America Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2029)
7.3.2 North America Tumor Immunotherapy Drugs Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2029)
8.2 Europe Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2029)
8.3 Europe Tumor Immunotherapy Drugs Market Size by Country
8.3.1 Europe Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2029)
8.3.2 Europe Tumor Immunotherapy Drugs Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Tumor Immunotherapy Drugs Market Size by Region
9.3.1 Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Tumor Immunotherapy Drugs Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2029)
10.2 South America Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2029)
10.3 South America Tumor Immunotherapy Drugs Market Size by Country
10.3.1 South America Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2029)
10.3.2 South America Tumor Immunotherapy Drugs Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Tumor Immunotherapy Drugs Market Size by Country
11.3.1 Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Tumor Immunotherapy Drugs Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Tumor Immunotherapy Drugs Market Drivers
12.2 Tumor Immunotherapy Drugs Market Restraints
12.3 Tumor Immunotherapy Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Tumor Immunotherapy Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Tumor Immunotherapy Drugs
13.3 Tumor Immunotherapy Drugs Production Process
13.4 Tumor Immunotherapy Drugs Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Tumor Immunotherapy Drugs Typical Distributors
14.3 Tumor Immunotherapy Drugs Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of Tumor Immunotherapy Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Tumor Immunotherapy Drugs Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Immune Checkpoint Inhibitors
1.3.3 Tumor Vaccine
1.3.4 Adoptive Immunotherapy
1.3.5 Non-specific Immunomodulator
1.4 Market Analysis by Application
1.4.1 Overview: Global Tumor Immunotherapy Drugs Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Other
1.5 Global Tumor Immunotherapy Drugs Market Size & Forecast
1.5.1 Global Tumor Immunotherapy Drugs Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Tumor Immunotherapy Drugs Sales Quantity (2018-2029)
1.5.3 Global Tumor Immunotherapy Drugs Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 Bristol Myer Squibb
2.1.1 Bristol Myer Squibb Details
2.1.2 Bristol Myer Squibb Major Business
2.1.3 Bristol Myer Squibb Tumor Immunotherapy Drugs Product and Services
2.1.4 Bristol Myer Squibb Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Bristol Myer Squibb Recent Developments/Updates
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Tumor Immunotherapy Drugs Product and Services
2.2.4 AstraZeneca Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 AstraZeneca Recent Developments/Updates
2.3 Merck
2.3.1 Merck Details
2.3.2 Merck Major Business
2.3.3 Merck Tumor Immunotherapy Drugs Product and Services
2.3.4 Merck Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Merck Recent Developments/Updates
2.4 Roche / Genentech
2.4.1 Roche / Genentech Details
2.4.2 Roche / Genentech Major Business
2.4.3 Roche / Genentech Tumor Immunotherapy Drugs Product and Services
2.4.4 Roche / Genentech Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Roche / Genentech Recent Developments/Updates
2.5 Ono Pharmaceutical
2.5.1 Ono Pharmaceutical Details
2.5.2 Ono Pharmaceutical Major Business
2.5.3 Ono Pharmaceutical Tumor Immunotherapy Drugs Product and Services
2.5.4 Ono Pharmaceutical Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Ono Pharmaceutical Recent Developments/Updates
2.6 Regeneron
2.6.1 Regeneron Details
2.6.2 Regeneron Major Business
2.6.3 Regeneron Tumor Immunotherapy Drugs Product and Services
2.6.4 Regeneron Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Regeneron Recent Developments/Updates
2.7 Innovent
2.7.1 Innovent Details
2.7.2 Innovent Major Business
2.7.3 Innovent Tumor Immunotherapy Drugs Product and Services
2.7.4 Innovent Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Innovent Recent Developments/Updates
2.8 Hengrui Medicine
2.8.1 Hengrui Medicine Details
2.8.2 Hengrui Medicine Major Business
2.8.3 Hengrui Medicine Tumor Immunotherapy Drugs Product and Services
2.8.4 Hengrui Medicine Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Hengrui Medicine Recent Developments/Updates
2.9 Junshi Biosciences
2.9.1 Junshi Biosciences Details
2.9.2 Junshi Biosciences Major Business
2.9.3 Junshi Biosciences Tumor Immunotherapy Drugs Product and Services
2.9.4 Junshi Biosciences Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Junshi Biosciences Recent Developments/Updates
2.10 Pfizer, Inc
2.10.1 Pfizer, Inc Details
2.10.2 Pfizer, Inc Major Business
2.10.3 Pfizer, Inc Tumor Immunotherapy Drugs Product and Services
2.10.4 Pfizer, Inc Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Pfizer, Inc Recent Developments/Updates
2.11 F. Hoffmann-La Roche Ltd
2.11.1 F. Hoffmann-La Roche Ltd Details
2.11.2 F. Hoffmann-La Roche Ltd Major Business
2.11.3 F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Product and Services
2.11.4 F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
2.12 Incyte Corporation
2.12.1 Incyte Corporation Details
2.12.2 Incyte Corporation Major Business
2.12.3 Incyte Corporation Tumor Immunotherapy Drugs Product and Services
2.12.4 Incyte Corporation Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Incyte Corporation Recent Developments/Updates
2.13 NewLink Genetics Corporation
2.13.1 NewLink Genetics Corporation Details
2.13.2 NewLink Genetics Corporation Major Business
2.13.3 NewLink Genetics Corporation Tumor Immunotherapy Drugs Product and Services
2.13.4 NewLink Genetics Corporation Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 NewLink Genetics Corporation Recent Developments/Updates
2.14 Celldex Therapeutics, Inc
2.14.1 Celldex Therapeutics, Inc Details
2.14.2 Celldex Therapeutics, Inc Major Business
2.14.3 Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Product and Services
2.14.4 Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Celldex Therapeutics, Inc Recent Developments/Updates
2.15 GlaxoSmithKline
2.15.1 GlaxoSmithKline Details
2.15.2 GlaxoSmithKline Major Business
2.15.3 GlaxoSmithKline Tumor Immunotherapy Drugs Product and Services
2.15.4 GlaxoSmithKline Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 GlaxoSmithKline Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: TUMOR IMMUNOTHERAPY DRUGS BY MANUFACTURER
3.1 Global Tumor Immunotherapy Drugs Sales Quantity by Manufacturer (2018-2023)
3.2 Global Tumor Immunotherapy Drugs Revenue by Manufacturer (2018-2023)
3.3 Global Tumor Immunotherapy Drugs Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Tumor Immunotherapy Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Tumor Immunotherapy Drugs Manufacturer Market Share in 2022
3.4.2 Top 6 Tumor Immunotherapy Drugs Manufacturer Market Share in 2022
3.5 Tumor Immunotherapy Drugs Market: Overall Company Footprint Analysis
3.5.1 Tumor Immunotherapy Drugs Market: Region Footprint
3.5.2 Tumor Immunotherapy Drugs Market: Company Product Type Footprint
3.5.3 Tumor Immunotherapy Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Tumor Immunotherapy Drugs Market Size by Region
4.1.1 Global Tumor Immunotherapy Drugs Sales Quantity by Region (2018-2029)
4.1.2 Global Tumor Immunotherapy Drugs Consumption Value by Region (2018-2029)
4.1.3 Global Tumor Immunotherapy Drugs Average Price by Region (2018-2029)
4.2 North America Tumor Immunotherapy Drugs Consumption Value (2018-2029)
4.3 Europe Tumor Immunotherapy Drugs Consumption Value (2018-2029)
4.4 Asia-Pacific Tumor Immunotherapy Drugs Consumption Value (2018-2029)
4.5 South America Tumor Immunotherapy Drugs Consumption Value (2018-2029)
4.6 Middle East and Africa Tumor Immunotherapy Drugs Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2029)
5.2 Global Tumor Immunotherapy Drugs Consumption Value by Type (2018-2029)
5.3 Global Tumor Immunotherapy Drugs Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2029)
6.2 Global Tumor Immunotherapy Drugs Consumption Value by Application (2018-2029)
6.3 Global Tumor Immunotherapy Drugs Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2029)
7.2 North America Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2029)
7.3 North America Tumor Immunotherapy Drugs Market Size by Country
7.3.1 North America Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2029)
7.3.2 North America Tumor Immunotherapy Drugs Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2029)
8.2 Europe Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2029)
8.3 Europe Tumor Immunotherapy Drugs Market Size by Country
8.3.1 Europe Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2029)
8.3.2 Europe Tumor Immunotherapy Drugs Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Tumor Immunotherapy Drugs Market Size by Region
9.3.1 Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Tumor Immunotherapy Drugs Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2029)
10.2 South America Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2029)
10.3 South America Tumor Immunotherapy Drugs Market Size by Country
10.3.1 South America Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2029)
10.3.2 South America Tumor Immunotherapy Drugs Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Tumor Immunotherapy Drugs Market Size by Country
11.3.1 Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Tumor Immunotherapy Drugs Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Tumor Immunotherapy Drugs Market Drivers
12.2 Tumor Immunotherapy Drugs Market Restraints
12.3 Tumor Immunotherapy Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Tumor Immunotherapy Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Tumor Immunotherapy Drugs
13.3 Tumor Immunotherapy Drugs Production Process
13.4 Tumor Immunotherapy Drugs Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Tumor Immunotherapy Drugs Typical Distributors
14.3 Tumor Immunotherapy Drugs Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Tumor Immunotherapy Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Tumor Immunotherapy Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Bristol Myer Squibb Basic Information, Manufacturing Base and Competitors
Table 4. Bristol Myer Squibb Major Business
Table 5. Bristol Myer Squibb Tumor Immunotherapy Drugs Product and Services
Table 6. Bristol Myer Squibb Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Bristol Myer Squibb Recent Developments/Updates
Table 8. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 9. AstraZeneca Major Business
Table 10. AstraZeneca Tumor Immunotherapy Drugs Product and Services
Table 11. AstraZeneca Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. AstraZeneca Recent Developments/Updates
Table 13. Merck Basic Information, Manufacturing Base and Competitors
Table 14. Merck Major Business
Table 15. Merck Tumor Immunotherapy Drugs Product and Services
Table 16. Merck Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Merck Recent Developments/Updates
Table 18. Roche / Genentech Basic Information, Manufacturing Base and Competitors
Table 19. Roche / Genentech Major Business
Table 20. Roche / Genentech Tumor Immunotherapy Drugs Product and Services
Table 21. Roche / Genentech Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Roche / Genentech Recent Developments/Updates
Table 23. Ono Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 24. Ono Pharmaceutical Major Business
Table 25. Ono Pharmaceutical Tumor Immunotherapy Drugs Product and Services
Table 26. Ono Pharmaceutical Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Ono Pharmaceutical Recent Developments/Updates
Table 28. Regeneron Basic Information, Manufacturing Base and Competitors
Table 29. Regeneron Major Business
Table 30. Regeneron Tumor Immunotherapy Drugs Product and Services
Table 31. Regeneron Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Regeneron Recent Developments/Updates
Table 33. Innovent Basic Information, Manufacturing Base and Competitors
Table 34. Innovent Major Business
Table 35. Innovent Tumor Immunotherapy Drugs Product and Services
Table 36. Innovent Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Innovent Recent Developments/Updates
Table 38. Hengrui Medicine Basic Information, Manufacturing Base and Competitors
Table 39. Hengrui Medicine Major Business
Table 40. Hengrui Medicine Tumor Immunotherapy Drugs Product and Services
Table 41. Hengrui Medicine Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Hengrui Medicine Recent Developments/Updates
Table 43. Junshi Biosciences Basic Information, Manufacturing Base and Competitors
Table 44. Junshi Biosciences Major Business
Table 45. Junshi Biosciences Tumor Immunotherapy Drugs Product and Services
Table 46. Junshi Biosciences Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Junshi Biosciences Recent Developments/Updates
Table 48. Pfizer, Inc Basic Information, Manufacturing Base and Competitors
Table 49. Pfizer, Inc Major Business
Table 50. Pfizer, Inc Tumor Immunotherapy Drugs Product and Services
Table 51. Pfizer, Inc Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Pfizer, Inc Recent Developments/Updates
Table 53. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table 54. F. Hoffmann-La Roche Ltd Major Business
Table 55. F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Product and Services
Table 56. F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 58. Incyte Corporation Basic Information, Manufacturing Base and Competitors
Table 59. Incyte Corporation Major Business
Table 60. Incyte Corporation Tumor Immunotherapy Drugs Product and Services
Table 61. Incyte Corporation Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Incyte Corporation Recent Developments/Updates
Table 63. NewLink Genetics Corporation Basic Information, Manufacturing Base and Competitors
Table 64. NewLink Genetics Corporation Major Business
Table 65. NewLink Genetics Corporation Tumor Immunotherapy Drugs Product and Services
Table 66. NewLink Genetics Corporation Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. NewLink Genetics Corporation Recent Developments/Updates
Table 68. Celldex Therapeutics, Inc Basic Information, Manufacturing Base and Competitors
Table 69. Celldex Therapeutics, Inc Major Business
Table 70. Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Product and Services
Table 71. Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Celldex Therapeutics, Inc Recent Developments/Updates
Table 73. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 74. GlaxoSmithKline Major Business
Table 75. GlaxoSmithKline Tumor Immunotherapy Drugs Product and Services
Table 76. GlaxoSmithKline Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. GlaxoSmithKline Recent Developments/Updates
Table 78. Global Tumor Immunotherapy Drugs Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 79. Global Tumor Immunotherapy Drugs Revenue by Manufacturer (2018-2023) & (USD Million)
Table 80. Global Tumor Immunotherapy Drugs Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 81. Market Position of Manufacturers in Tumor Immunotherapy Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 82. Head Office and Tumor Immunotherapy Drugs Production Site of Key Manufacturer
Table 83. Tumor Immunotherapy Drugs Market: Company Product Type Footprint
Table 84. Tumor Immunotherapy Drugs Market: Company Product Application Footprint
Table 85. Tumor Immunotherapy Drugs New Market Entrants and Barriers to Market Entry
Table 86. Tumor Immunotherapy Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 87. Global Tumor Immunotherapy Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 88. Global Tumor Immunotherapy Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 89. Global Tumor Immunotherapy Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 90. Global Tumor Immunotherapy Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 91. Global Tumor Immunotherapy Drugs Average Price by Region (2018-2023) & (US$/Unit)
Table 92. Global Tumor Immunotherapy Drugs Average Price by Region (2024-2029) & (US$/Unit)
Table 93. Global Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 94. Global Tumor Immunotherapy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 95. Global Tumor Immunotherapy Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 96. Global Tumor Immunotherapy Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 97. Global Tumor Immunotherapy Drugs Average Price by Type (2018-2023) & (US$/Unit)
Table 98. Global Tumor Immunotherapy Drugs Average Price by Type (2024-2029) & (US$/Unit)
Table 99. Global Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 100. Global Tumor Immunotherapy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 101. Global Tumor Immunotherapy Drugs Consumption Value by Application (2018-2023) & (USD Million)
Table 102. Global Tumor Immunotherapy Drugs Consumption Value by Application (2024-2029) & (USD Million)
Table 103. Global Tumor Immunotherapy Drugs Average Price by Application (2018-2023) & (US$/Unit)
Table 104. Global Tumor Immunotherapy Drugs Average Price by Application (2024-2029) & (US$/Unit)
Table 105. North America Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 106. North America Tumor Immunotherapy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 107. North America Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 108. North America Tumor Immunotherapy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 109. North America Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 110. North America Tumor Immunotherapy Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 111. North America Tumor Immunotherapy Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 112. North America Tumor Immunotherapy Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 113. Europe Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 114. Europe Tumor Immunotherapy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 115. Europe Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 116. Europe Tumor Immunotherapy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 117. Europe Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 118. Europe Tumor Immunotherapy Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 119. Europe Tumor Immunotherapy Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 120. Europe Tumor Immunotherapy Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 121. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 122. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 123. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 124. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 125. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 126. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 127. Asia-Pacific Tumor Immunotherapy Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 128. Asia-Pacific Tumor Immunotherapy Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 129. South America Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 130. South America Tumor Immunotherapy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 131. South America Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 132. South America Tumor Immunotherapy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 133. South America Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 134. South America Tumor Immunotherapy Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 135. South America Tumor Immunotherapy Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 136. South America Tumor Immunotherapy Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 137. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 138. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 139. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 140. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 141. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 142. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 143. Middle East & Africa Tumor Immunotherapy Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 144. Middle East & Africa Tumor Immunotherapy Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 145. Tumor Immunotherapy Drugs Raw Material
Table 146. Key Manufacturers of Tumor Immunotherapy Drugs Raw Materials
Table 147. Tumor Immunotherapy Drugs Typical Distributors
Table 148. Tumor Immunotherapy Drugs Typical Customers
List of Figures
Figure 1. Tumor Immunotherapy Drugs Picture
Figure 2. Global Tumor Immunotherapy Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Tumor Immunotherapy Drugs Consumption Value Market Share by Type in 2022
Figure 4. Immune Checkpoint Inhibitors Examples
Figure 5. Tumor Vaccine Examples
Figure 6. Adoptive Immunotherapy Examples
Figure 7. Non-specific Immunomodulator Examples
Figure 8. Global Tumor Immunotherapy Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 9. Global Tumor Immunotherapy Drugs Consumption Value Market Share by Application in 2022
Figure 10. Hospital Examples
Figure 11. Clinic Examples
Figure 12. Other Examples
Figure 13. Global Tumor Immunotherapy Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Tumor Immunotherapy Drugs Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Tumor Immunotherapy Drugs Sales Quantity (2018-2029) & (K Units)
Figure 16. Global Tumor Immunotherapy Drugs Average Price (2018-2029) & (US$/Unit)
Figure 17. Global Tumor Immunotherapy Drugs Sales Quantity Market Share by Manufacturer in 2022
Figure 18. Global Tumor Immunotherapy Drugs Consumption Value Market Share by Manufacturer in 2022
Figure 19. Producer Shipments of Tumor Immunotherapy Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 20. Top 3 Tumor Immunotherapy Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Top 6 Tumor Immunotherapy Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Global Tumor Immunotherapy Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 23. Global Tumor Immunotherapy Drugs Consumption Value Market Share by Region (2018-2029)
Figure 24. North America Tumor Immunotherapy Drugs Consumption Value (2018-2029) & (USD Million)
Figure 25. Europe Tumor Immunotherapy Drugs Consumption Value (2018-2029) & (USD Million)
Figure 26. Asia-Pacific Tumor Immunotherapy Drugs Consumption Value (2018-2029) & (USD Million)
Figure 27. South America Tumor Immunotherapy Drugs Consumption Value (2018-2029) & (USD Million)
Figure 28. Middle East & Africa Tumor Immunotherapy Drugs Consumption Value (2018-2029) & (USD Million)
Figure 29. Global Tumor Immunotherapy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 30. Global Tumor Immunotherapy Drugs Consumption Value Market Share by Type (2018-2029)
Figure 31. Global Tumor Immunotherapy Drugs Average Price by Type (2018-2029) & (US$/Unit)
Figure 32. Global Tumor Immunotherapy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 33. Global Tumor Immunotherapy Drugs Consumption Value Market Share by Application (2018-2029)
Figure 34. Global Tumor Immunotherapy Drugs Average Price by Application (2018-2029) & (US$/Unit)
Figure 35. North America Tumor Immunotherapy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 36. North America Tumor Immunotherapy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 37. North America Tumor Immunotherapy Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 38. North America Tumor Immunotherapy Drugs Consumption Value Market Share by Country (2018-2029)
Figure 39. United States Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Canada Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Mexico Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Europe Tumor Immunotherapy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 43. Europe Tumor Immunotherapy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 44. Europe Tumor Immunotherapy Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 45. Europe Tumor Immunotherapy Drugs Consumption Value Market Share by Country (2018-2029)
Figure 46. Germany Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. France Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. United Kingdom Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Russia Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Italy Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 52. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 53. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 54. Asia-Pacific Tumor Immunotherapy Drugs Consumption Value Market Share by Region (2018-2029)
Figure 55. China Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Japan Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Korea Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. India Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Southeast Asia Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Australia Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. South America Tumor Immunotherapy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 62. South America Tumor Immunotherapy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 63. South America Tumor Immunotherapy Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 64. South America Tumor Immunotherapy Drugs Consumption Value Market Share by Country (2018-2029)
Figure 65. Brazil Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Argentina Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 68. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 69. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 70. Middle East & Africa Tumor Immunotherapy Drugs Consumption Value Market Share by Region (2018-2029)
Figure 71. Turkey Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Egypt Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Saudi Arabia Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. South Africa Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Tumor Immunotherapy Drugs Market Drivers
Figure 76. Tumor Immunotherapy Drugs Market Restraints
Figure 77. Tumor Immunotherapy Drugs Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Tumor Immunotherapy Drugs in 2022
Figure 80. Manufacturing Process Analysis of Tumor Immunotherapy Drugs
Figure 81. Tumor Immunotherapy Drugs Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
Table 1. Global Tumor Immunotherapy Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Tumor Immunotherapy Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Bristol Myer Squibb Basic Information, Manufacturing Base and Competitors
Table 4. Bristol Myer Squibb Major Business
Table 5. Bristol Myer Squibb Tumor Immunotherapy Drugs Product and Services
Table 6. Bristol Myer Squibb Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Bristol Myer Squibb Recent Developments/Updates
Table 8. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 9. AstraZeneca Major Business
Table 10. AstraZeneca Tumor Immunotherapy Drugs Product and Services
Table 11. AstraZeneca Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. AstraZeneca Recent Developments/Updates
Table 13. Merck Basic Information, Manufacturing Base and Competitors
Table 14. Merck Major Business
Table 15. Merck Tumor Immunotherapy Drugs Product and Services
Table 16. Merck Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Merck Recent Developments/Updates
Table 18. Roche / Genentech Basic Information, Manufacturing Base and Competitors
Table 19. Roche / Genentech Major Business
Table 20. Roche / Genentech Tumor Immunotherapy Drugs Product and Services
Table 21. Roche / Genentech Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Roche / Genentech Recent Developments/Updates
Table 23. Ono Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 24. Ono Pharmaceutical Major Business
Table 25. Ono Pharmaceutical Tumor Immunotherapy Drugs Product and Services
Table 26. Ono Pharmaceutical Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Ono Pharmaceutical Recent Developments/Updates
Table 28. Regeneron Basic Information, Manufacturing Base and Competitors
Table 29. Regeneron Major Business
Table 30. Regeneron Tumor Immunotherapy Drugs Product and Services
Table 31. Regeneron Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Regeneron Recent Developments/Updates
Table 33. Innovent Basic Information, Manufacturing Base and Competitors
Table 34. Innovent Major Business
Table 35. Innovent Tumor Immunotherapy Drugs Product and Services
Table 36. Innovent Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Innovent Recent Developments/Updates
Table 38. Hengrui Medicine Basic Information, Manufacturing Base and Competitors
Table 39. Hengrui Medicine Major Business
Table 40. Hengrui Medicine Tumor Immunotherapy Drugs Product and Services
Table 41. Hengrui Medicine Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Hengrui Medicine Recent Developments/Updates
Table 43. Junshi Biosciences Basic Information, Manufacturing Base and Competitors
Table 44. Junshi Biosciences Major Business
Table 45. Junshi Biosciences Tumor Immunotherapy Drugs Product and Services
Table 46. Junshi Biosciences Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Junshi Biosciences Recent Developments/Updates
Table 48. Pfizer, Inc Basic Information, Manufacturing Base and Competitors
Table 49. Pfizer, Inc Major Business
Table 50. Pfizer, Inc Tumor Immunotherapy Drugs Product and Services
Table 51. Pfizer, Inc Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Pfizer, Inc Recent Developments/Updates
Table 53. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table 54. F. Hoffmann-La Roche Ltd Major Business
Table 55. F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Product and Services
Table 56. F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 58. Incyte Corporation Basic Information, Manufacturing Base and Competitors
Table 59. Incyte Corporation Major Business
Table 60. Incyte Corporation Tumor Immunotherapy Drugs Product and Services
Table 61. Incyte Corporation Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Incyte Corporation Recent Developments/Updates
Table 63. NewLink Genetics Corporation Basic Information, Manufacturing Base and Competitors
Table 64. NewLink Genetics Corporation Major Business
Table 65. NewLink Genetics Corporation Tumor Immunotherapy Drugs Product and Services
Table 66. NewLink Genetics Corporation Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. NewLink Genetics Corporation Recent Developments/Updates
Table 68. Celldex Therapeutics, Inc Basic Information, Manufacturing Base and Competitors
Table 69. Celldex Therapeutics, Inc Major Business
Table 70. Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Product and Services
Table 71. Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Celldex Therapeutics, Inc Recent Developments/Updates
Table 73. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 74. GlaxoSmithKline Major Business
Table 75. GlaxoSmithKline Tumor Immunotherapy Drugs Product and Services
Table 76. GlaxoSmithKline Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. GlaxoSmithKline Recent Developments/Updates
Table 78. Global Tumor Immunotherapy Drugs Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 79. Global Tumor Immunotherapy Drugs Revenue by Manufacturer (2018-2023) & (USD Million)
Table 80. Global Tumor Immunotherapy Drugs Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 81. Market Position of Manufacturers in Tumor Immunotherapy Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 82. Head Office and Tumor Immunotherapy Drugs Production Site of Key Manufacturer
Table 83. Tumor Immunotherapy Drugs Market: Company Product Type Footprint
Table 84. Tumor Immunotherapy Drugs Market: Company Product Application Footprint
Table 85. Tumor Immunotherapy Drugs New Market Entrants and Barriers to Market Entry
Table 86. Tumor Immunotherapy Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 87. Global Tumor Immunotherapy Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 88. Global Tumor Immunotherapy Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 89. Global Tumor Immunotherapy Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 90. Global Tumor Immunotherapy Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 91. Global Tumor Immunotherapy Drugs Average Price by Region (2018-2023) & (US$/Unit)
Table 92. Global Tumor Immunotherapy Drugs Average Price by Region (2024-2029) & (US$/Unit)
Table 93. Global Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 94. Global Tumor Immunotherapy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 95. Global Tumor Immunotherapy Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 96. Global Tumor Immunotherapy Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 97. Global Tumor Immunotherapy Drugs Average Price by Type (2018-2023) & (US$/Unit)
Table 98. Global Tumor Immunotherapy Drugs Average Price by Type (2024-2029) & (US$/Unit)
Table 99. Global Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 100. Global Tumor Immunotherapy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 101. Global Tumor Immunotherapy Drugs Consumption Value by Application (2018-2023) & (USD Million)
Table 102. Global Tumor Immunotherapy Drugs Consumption Value by Application (2024-2029) & (USD Million)
Table 103. Global Tumor Immunotherapy Drugs Average Price by Application (2018-2023) & (US$/Unit)
Table 104. Global Tumor Immunotherapy Drugs Average Price by Application (2024-2029) & (US$/Unit)
Table 105. North America Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 106. North America Tumor Immunotherapy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 107. North America Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 108. North America Tumor Immunotherapy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 109. North America Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 110. North America Tumor Immunotherapy Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 111. North America Tumor Immunotherapy Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 112. North America Tumor Immunotherapy Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 113. Europe Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 114. Europe Tumor Immunotherapy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 115. Europe Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 116. Europe Tumor Immunotherapy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 117. Europe Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 118. Europe Tumor Immunotherapy Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 119. Europe Tumor Immunotherapy Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 120. Europe Tumor Immunotherapy Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 121. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 122. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 123. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 124. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 125. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 126. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 127. Asia-Pacific Tumor Immunotherapy Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 128. Asia-Pacific Tumor Immunotherapy Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 129. South America Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 130. South America Tumor Immunotherapy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 131. South America Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 132. South America Tumor Immunotherapy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 133. South America Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 134. South America Tumor Immunotherapy Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 135. South America Tumor Immunotherapy Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 136. South America Tumor Immunotherapy Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 137. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 138. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 139. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 140. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 141. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 142. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 143. Middle East & Africa Tumor Immunotherapy Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 144. Middle East & Africa Tumor Immunotherapy Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 145. Tumor Immunotherapy Drugs Raw Material
Table 146. Key Manufacturers of Tumor Immunotherapy Drugs Raw Materials
Table 147. Tumor Immunotherapy Drugs Typical Distributors
Table 148. Tumor Immunotherapy Drugs Typical Customers
List of Figures
Figure 1. Tumor Immunotherapy Drugs Picture
Figure 2. Global Tumor Immunotherapy Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Tumor Immunotherapy Drugs Consumption Value Market Share by Type in 2022
Figure 4. Immune Checkpoint Inhibitors Examples
Figure 5. Tumor Vaccine Examples
Figure 6. Adoptive Immunotherapy Examples
Figure 7. Non-specific Immunomodulator Examples
Figure 8. Global Tumor Immunotherapy Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 9. Global Tumor Immunotherapy Drugs Consumption Value Market Share by Application in 2022
Figure 10. Hospital Examples
Figure 11. Clinic Examples
Figure 12. Other Examples
Figure 13. Global Tumor Immunotherapy Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Tumor Immunotherapy Drugs Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Tumor Immunotherapy Drugs Sales Quantity (2018-2029) & (K Units)
Figure 16. Global Tumor Immunotherapy Drugs Average Price (2018-2029) & (US$/Unit)
Figure 17. Global Tumor Immunotherapy Drugs Sales Quantity Market Share by Manufacturer in 2022
Figure 18. Global Tumor Immunotherapy Drugs Consumption Value Market Share by Manufacturer in 2022
Figure 19. Producer Shipments of Tumor Immunotherapy Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 20. Top 3 Tumor Immunotherapy Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Top 6 Tumor Immunotherapy Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Global Tumor Immunotherapy Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 23. Global Tumor Immunotherapy Drugs Consumption Value Market Share by Region (2018-2029)
Figure 24. North America Tumor Immunotherapy Drugs Consumption Value (2018-2029) & (USD Million)
Figure 25. Europe Tumor Immunotherapy Drugs Consumption Value (2018-2029) & (USD Million)
Figure 26. Asia-Pacific Tumor Immunotherapy Drugs Consumption Value (2018-2029) & (USD Million)
Figure 27. South America Tumor Immunotherapy Drugs Consumption Value (2018-2029) & (USD Million)
Figure 28. Middle East & Africa Tumor Immunotherapy Drugs Consumption Value (2018-2029) & (USD Million)
Figure 29. Global Tumor Immunotherapy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 30. Global Tumor Immunotherapy Drugs Consumption Value Market Share by Type (2018-2029)
Figure 31. Global Tumor Immunotherapy Drugs Average Price by Type (2018-2029) & (US$/Unit)
Figure 32. Global Tumor Immunotherapy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 33. Global Tumor Immunotherapy Drugs Consumption Value Market Share by Application (2018-2029)
Figure 34. Global Tumor Immunotherapy Drugs Average Price by Application (2018-2029) & (US$/Unit)
Figure 35. North America Tumor Immunotherapy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 36. North America Tumor Immunotherapy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 37. North America Tumor Immunotherapy Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 38. North America Tumor Immunotherapy Drugs Consumption Value Market Share by Country (2018-2029)
Figure 39. United States Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Canada Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Mexico Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Europe Tumor Immunotherapy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 43. Europe Tumor Immunotherapy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 44. Europe Tumor Immunotherapy Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 45. Europe Tumor Immunotherapy Drugs Consumption Value Market Share by Country (2018-2029)
Figure 46. Germany Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. France Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. United Kingdom Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Russia Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Italy Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 52. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 53. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 54. Asia-Pacific Tumor Immunotherapy Drugs Consumption Value Market Share by Region (2018-2029)
Figure 55. China Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Japan Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Korea Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. India Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Southeast Asia Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Australia Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. South America Tumor Immunotherapy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 62. South America Tumor Immunotherapy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 63. South America Tumor Immunotherapy Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 64. South America Tumor Immunotherapy Drugs Consumption Value Market Share by Country (2018-2029)
Figure 65. Brazil Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Argentina Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 68. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 69. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 70. Middle East & Africa Tumor Immunotherapy Drugs Consumption Value Market Share by Region (2018-2029)
Figure 71. Turkey Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Egypt Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Saudi Arabia Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. South Africa Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Tumor Immunotherapy Drugs Market Drivers
Figure 76. Tumor Immunotherapy Drugs Market Restraints
Figure 77. Tumor Immunotherapy Drugs Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Tumor Immunotherapy Drugs in 2022
Figure 80. Manufacturing Process Analysis of Tumor Immunotherapy Drugs
Figure 81. Tumor Immunotherapy Drugs Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
